These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23154560)

  • 1. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
    Matsubara D; Kanai Y; Ishikawa S; Ohara S; Yoshimoto T; Sakatani T; Oguni S; Tamura T; Kataoka H; Endo S; Murakami Y; Aburatani H; Fukayama M; Niki T
    J Thorac Oncol; 2012 Dec; 7(12):1872-1876. PubMed ID: 23154560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
    Suzuki M; Makinoshima H; Matsumoto S; Suzuki A; Mimaki S; Matsushima K; Yoh K; Goto K; Suzuki Y; Ishii G; Ochiai A; Tsuta K; Shibata T; Kohno T; Esumi H; Tsuchihara K
    Cancer Sci; 2013 Jul; 104(7):896-903. PubMed ID: 23578175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
    Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
    Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RET fusion genes in Korean non-small cell lung cancer.
    Yoo SS; Jin G; Jung HJ; Hong MJ; Choi JE; Jeon HS; Lee SY; Lim JO; Park JY
    J Korean Med Sci; 2013 Oct; 28(10):1555-8. PubMed ID: 24133367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET, ROS1 and ALK fusions in lung cancer.
    Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y
    Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
    Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
    Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis.
    Lin C; Wang S; Xie W; Chang J; Gan Y
    Cancer Biol Ther; 2015; 16(7):1019-28. PubMed ID: 25975578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC.
    Shiba-Ishii A; Isagawa T; Shiozawa T; Mato N; Nakagawa T; Takada Y; Hirai K; Hong J; Saitoh A; Takeda N; Niki T; Murakami Y; Matsubara D
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167249. PubMed ID: 38768929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma.
    Song Z; Yu X; Zhang Y
    Lung Cancer; 2016 Nov; 101():16-21. PubMed ID: 27794403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.
    Wijesinghe P; Bepler G; Bollig-Fischer A
    J Thorac Oncol; 2015 Feb; 10(2):381-6. PubMed ID: 25384172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.
    Lee MS; Kim RN; I H; Oh DY; Song JY; Noh KW; Kim YJ; Yang JW; Lira ME; Lee CH; Lee MK; Kim YD; Mao M; Han J; Kim J; Choi YL
    Oncotarget; 2016 Jun; 7(24):36101-36114. PubMed ID: 27150058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
    Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
    Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
    Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
    Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
    Wang R; Hu H; Pan Y; Li Y; Ye T; Li C; Luo X; Wang L; Li H; Zhang Y; Li F; Lu Y; Lu Q; Xu J; Garfield D; Shen L; Ji H; Pao W; Sun Y; Chen H
    J Clin Oncol; 2012 Dec; 30(35):4352-9. PubMed ID: 23150706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
    Sarfaty M; Moore A; Neiman V; Dudnik E; Ilouze M; Gottfried M; Katznelson R; Nechushtan H; Sorotsky HG; Paz K; Katz A; Saute M; Wolner M; Moskovitz M; Miller V; Elvin J; Lipson D; Ali S; Gutman LS; Dvir A; Gordon N; Peled N
    Clin Lung Cancer; 2017 Jul; 18(4):e223-e232. PubMed ID: 28082048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.
    Tsuta K; Kohno T; Yoshida A; Shimada Y; Asamura H; Furuta K; Kushima R
    Br J Cancer; 2014 Mar; 110(6):1571-8. PubMed ID: 24504365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Human-Derived
    Schubert L; Le AT; Estrada-Bernal A; Doak AE; Yoo M; Ferrara SE; Goodspeed A; Kinose F; Rix U; Tan AC; Doebele RC
    Mol Pharmacol; 2021 Jun; 99(6):435-447. PubMed ID: 33795352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells.
    Hirai S; Idogawa M; Sumi T; Yamaguchi M; Niki T; Sakuma Y
    Biochem Biophys Res Commun; 2022 Nov; 630():24-29. PubMed ID: 36126466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.